Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory committee cancellations

Executive Summary

A Psychopharmacologic Drugs Advisory Committee review of Wyeth's pending antidepressant desvenlafaxine scheduled for Sept. 8 has been canceled, Wyeth announces Aug. 22. FDA deemed the meeting unnecessary because "questions that they had were answered with further review of the data," firm says. Company still expects to launch the Effexor follow-on in 2007. The agency also recently cancelled a Sept. 7 psychopharm committee review of J&J's antipsychotic paliperidone (1"The Pink Sheet" July 24, 2006, p. 6). Additionally, Schering-Plough announced Aug. 21 that a planned Sept. 11 Anti-Infective Drugs Advisory Committee review of garenoxacin (proposed trade name Geninax) has been cancelled after the company withdrew the NDA. Schering says it may meet with FDA in the future about a resubmission of the antibiotic...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS047506

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel